YAP/TAZ‐TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma
Open Access
- 12 April 2024
- journal article
- review article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (8) , e18330
Abstract
The Hippo signalling pathway, a highly conserved signalling cassette, regulates organ size by controlling cell growth, apoptosis and stem cell self‐renewal. The tumourigenic potential of this pathway is largely attributed to the activity of YAP/TAZ, which activate the TEAD1‐4 transcription factors, leading to the expression of genes involved in cell proliferation and suppression of cell death. Aberrant regulation of the YAP/TAZ‐TEAD signalling axis is commonly observed in malignant pleural mesothelioma (MPM), an insidious neoplasm of the pleural tissue that lines the chest cavity and covers the lungs with poor prognosis. Given the limited effectiveness of current treatments, targeting the YAP/TAZ‐TEAD signalling cascade has emerged as a promising therapeutic strategy in MPM. Several inhibitors of the YAP/TAZ‐TEAD signalling axis are presently undergoing clinical development, with the goal of advancing them to clinical use in the near future.Keywords
This publication has 40 references indexed in Scilit:
- YAP/TAZ upstream signals and downstream responsesNature Cell Biology, 2018
- Multifaceted regulation and functions of YAP/TAZ in tumors (Review)Oncology Reports, 2018
- Homeostatic Control of Hpo/MST Kinase Activity through Autophosphorylation-Dependent Recruitment of the STRIPAK PP2A Phosphatase ComplexCell Reports, 2017
- β1 integrin–dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlinJournal of Biological Chemistry, 2017
- Gene expression profiling of calcifications in breast cancerScientific Reports, 2017
- SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinomaOncogene, 2013
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical TrialsJournal of Thoracic Oncology, 2010
- FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activitiesCancer Chemotherapy and Pharmacology, 2006
- Non‐palpable breast carcinomas: Correlation of mammographically detected malignant‐appearing microcalcifications and molecular prognostic factorsInternational Journal of Cancer, 2002